Literature DB >> 445966

Identification and quantitation of hydrazine in the urine of patients treated with hydralazine.

J A Timbrell, S J Harland.   

Abstract

Hydrazine has been identified by gas chromatography-mass spectrometry in the 0- to 24-hr urine of patients administered hydralazine. With a specific gas chromatographic assay procedure, the amount of hydrazine in the 0- to 24-hr urine was determined in patients treated with various doses of hydralazine. The amount of hydrazine detected in the urine was greater in the slow acetylator phenotype than in the rapid acetylator phenotype. Studies indicated that hydrazine was not produced by chemical breakdown of hydralazine or its known metabolites in urine and therefore was unlikely to be a urinary artefact formed by chemical decomposition in the urine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445966     DOI: 10.1002/cpt197926181

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Prescribing drugs for the elderly: reaching therapeutic goals.

Authors:  H G Preiksaitis; M Gordon
Journal:  Can Fam Physician       Date:  1986-12       Impact factor: 3.275

2.  Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.

Authors:  P Brunel; J B Lecaillon; T T Guyene; P Imhof; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

4.  Hydrallazine-induced hepatitis?

Authors:  D B Barnett; S A Hudson; P W Golightly
Journal:  Br Med J       Date:  1980-05-10

5.  Proton NMR spectroscopic studies on the metabolism and biochemical effects of hydrazine in vivo.

Authors:  S M Sanins; J A Timbrell; C Elcombe; J K Nicholson
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

6.  Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo.

Authors:  A M Jenner; J A Timbrell
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

Review 7.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

8.  Hydralazine use in relation to cancers of the lung, colon, and rectum.

Authors:  D W Kaufman; J P Kelly; L Rosenberg; P D Stolley; M E Warshauer; S Shapiro
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Hydralazine-induced lupus: is there a toxic metabolic pathway?

Authors:  J A Timbrell; V Facchini; S J Harland; R Mansilla-Tinoco
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Effect of acute and repeated exposure to low doses of hydrazine on hepatic microsomal enzymes and biochemical parameters in vivo.

Authors:  A M Jenner; J A Timbrell
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.